Regeneron (REGN) Tops Q2 EPS by 75c
Get Alerts REGN Hot Sheet
Revenue Growth %: +2.2%
Financial Fact:
Other collaboration revenue: 191.3M
Today's EPS Names:
WF, CWBC, GLTO, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q2 EPS of $5.45, $0.75 better than the analyst estimate of $4.70. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.56 billion.
- Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and second quarter 2018 non-GAAP net income per diluted share increased 31% to $5.45 versus second quarter 2017
- Second quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 8% to $992 million versus second quarter 2017 and second quarter 2018 EYLEA global net sales(1) increased 13% to $1.66 billion versus second quarter 2017
- Positive results reported from Phase 3 trial of Dupixent® (dupilumab) in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
GUIDANCE:
The Company's updated full year 2018 financial guidance consists of the following components:
Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses | $455 million–$485 million (previously $450 million–$485 million) |
Non-GAAP unreimbursed R&D(2)(4) | $1.210 billion–$1.260 billion (previously $1.230 billion–$1.310 billion) |
Non-GAAP SG&A(2)(4) | $1.340 billion–$1.390 billion (previously $1.325 billion–$1.395 billion) |
Effective tax rate | 13%–16% (previously 15%–18%) |
Capital expenditures | $410 million–$450 million (previously $420 million–$480 million) |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $1,030 at TD Cowen
- NOV Inc (NOV) Tops Q1 EPS by 3c; offers guidance
- Nomura Holdings (NMR) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!